NECTAR LIFESCIENCES Financial Statement Analysis
|
||
|
The Revenues of NECTAR LIFESCIENCES have decreased by -0.84% YoY .
The Earnings Per Share (EPS) of NECTAR LIFESCIENCES has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
NECTAR LIFESCIENCES Last 5 Annual Financial Results
[BOM: 532649|NSE : NECLIFE]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹1,670 Cr | ₹1,684 Cr | ₹1,524 Cr | ₹1,669 Cr | ₹1,543 Cr |
| Expenses | ₹1,700 Cr | ₹1,533 Cr | ₹1,471 Cr | ₹1,510 Cr | ₹1,442 Cr |
| Operating Profit (Excl OI) | ₹-30 Cr | ₹152 Cr | ₹53 Cr | ₹159 Cr | ₹101 Cr |
| Other Income | ₹7.47 Cr | ₹17 Cr | ₹53 Cr | ₹11 Cr | ₹11 Cr |
| Interest | ₹77 Cr | ₹90 Cr | ₹89 Cr | ₹79 Cr | ₹112 Cr |
| Depreciation | ₹62 Cr | ₹61 Cr | ₹59 Cr | ₹57 Cr | ₹60 Cr |
| Profit Before Tax | ₹-162 Cr | ₹18 Cr | ₹-42 Cr | ₹34 Cr | ₹-85 Cr |
| Profit After Tax | ₹-114 Cr | ₹5.00 Cr | ₹-24 Cr | ₹25 Cr | ₹-73 Cr |
| Consolidated Net Profit | ₹-114 Cr | ₹5.00 Cr | ₹-24 Cr | ₹25 Cr | ₹-73 Cr |
| Earnings Per Share (Rs) | ₹-5.07 | ₹0.22 | ₹-1.08 | ₹1.12 | ₹-3.27 |
| PAT Margin (%) | -5.96 | 0.26 | -1.38 | 1.30 | -4.15 |
| ROE(%) | -11.23 | 0.47 | -2.25 | 2.33 | -6.67 |
| ROCE(%) | -5.21 | 6.12 | 2.49 | 5.77 | 1.41 |
| Total Debt/Equity(x) | 0.61 | 0.59 | 0.71 | 0.79 | 0.85 |
Key Financials |
||
| Market Cap | : | ₹ 260.8 Cr |
| Revenue (TTM) | : | ₹ 717.1 Cr |
| Net Profit(TTM) | : | ₹ -126.0 Cr |
| EPS (TTM) | : | ₹ -6.5 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NECTAR LIFESCIENCES | -5.4% | -27.9% | -64.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.8% | -7.5% | -12.2% |
| DIVIS LABORATORIES | -0.6% | -5.5% | 6.1% |
| CIPLA | -3.7% | -11.7% | -8.5% |
| TORRENT PHARMACEUTICALS | -2.5% | 3.5% | 21.1% |
| DR REDDYS LABORATORIES | -0.7% | -4.7% | -5.1% |
| MANKIND PHARMA | -2.1% | -3.7% | -19.6% |
| ZYDUS LIFESCIENCES | 0.6% | -1.5% | -9.3% |
| LUPIN | -1.5% | 2.5% | -1.3% |
NECTAR LIFESCIENCES Revenues
[BOM: 532649|NSE : NECLIFE]
| Y-o-Y | -0.84 % |
| 5 Yr CAGR | 1.99 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,670 Cr | -0.84 | |
| Mar2024 | ₹1,684 Cr | 10.53 | |
| Mar2023 | ₹1,524 Cr | -8.70 | |
| Mar2022 | ₹1,669 Cr | 8.13 | |
| Mar2021 | ₹1,543 Cr | - | |
NECTAR LIFESCIENCES Operating Profit
[BOM: 532649|NSE : NECLIFE]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹-30 Cr | Negative | |
| Mar2024 | ₹152 Cr | 185.91 | |
| Mar2023 | ₹53 Cr | -66.57 | |
| Mar2022 | ₹159 Cr | 56.27 | |
| Mar2021 | ₹101 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | -1.77% | Negative | |
| Mar2024 | 9% | 158.62 | |
| Mar2023 | 3.48% | -63.37 | |
| Mar2022 | 9.5% | 44.60 | |
| Mar2021 | 6.57% | - | |
NECTAR LIFESCIENCES Profit After Tax
[BOM: 532649|NSE : NECLIFE]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹-114 Cr | Negative | |
| Mar2024 | ₹5.00 Cr | Positive | |
| Mar2023 | ₹-24 Cr | Negative | |
| Mar2022 | ₹25 Cr | Positive | |
| Mar2021 | ₹-73 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | -5.96 % | Negative | |
| Mar2024 | 0.26 % | Positive | |
| Mar2023 | -1.38 % | Negative | |
| Mar2022 | 1.3 % | Positive | |
| Mar2021 | -4.15 % | - | |
NECTAR LIFESCIENCES Earnings Per Share (EPS)
[BOM: 532649|NSE : NECLIFE]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹-5.07 | Negative | |
| Mar2024 | ₹0.22 | Positive | |
| Mar2023 | ₹-1.08 | Negative | |
| Mar2022 | ₹1.12 | Positive | |
| Mar2021 | ₹-3.27 | - | |
NECTAR LIFESCIENCES Return on Capital Employed (ROCE)
[BOM: 532649|NSE : NECLIFE]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | -5.21% | Negative | |
| Mar2024 | 6.12% | 145.78 | |
| Mar2023 | 2.49% | -56.85 | |
| Mar2022 | 5.77% | 309.22 | |
| Mar2021 | 1.41% | - | |
NECTAR LIFESCIENCES Share Price vs Sensex
| Current Share Price | : | ₹13.4 |
| Current MarketCap | : | ₹ 260.8 Cr |
| Updated EOD on | : | Jan 30,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NECTAR LIFESCIENCES | -5.4% |
-27.9% |
-64.8% |
| SENSEX | 0.8% |
-2.9% |
8.1% |
NECTAR LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE HEALTHCARE | -1.1% | -6.7% | -4% |
| BSE SMALLCAP | -5.8% | -8.9% | -10.5% |
No NSE index found
You may also like the below Video Courses
FAQ about NECTAR LIFESCIENCES Financials
How the annual revenues of NECTAR LIFESCIENCES have changed ?
The Revenues of NECTAR LIFESCIENCES have decreased by -0.84% YoY .
How the Earnings per Share (EPS) of NECTAR LIFESCIENCES have changed?
The Earnings Per Share (EPS) of NECTAR LIFESCIENCES has decreased by Negative YoY .
Check out Intrinsic Value of Peers of NECTAR LIFESCIENCES
Compare Stock Analytics of Peers of NECTAR LIFESCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
